Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5- fluorouracil (CMF) in node-positive breast cancer

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1693-1700

  Colleoni, M ^a   Price, K ^b,k   Castiglione Gertsch, M ^c   Goldhirsch, A ^a,d,j   Coates, A ^e   Lindtner, J ^e,f   Collins, J ^g   Gelber, R D ^b   Thurlimann B ^h   Rudenstam, C M ^i,q   Castiglione, M ^j   Davis, B ^j   Hartmann, W ^j   Bettelheim, R ^j   Neville, A M ^j   Zava, D ^j   Misteli, S ^j   Gelber, R ^k   Zelen, M ^k   Peterson, H ^k   Isley, M ^b   Parsons, M ^b   Szymoniak, L ^b   Hinkle, R ^b   Kay, R G ^l   Holdaway, I M ^l   Harvey, V J ^l   Jagusch, M F ^l   Neave, L ^l   Mason, B M ^l   Evans, B ^l   Benjamin, C S ^l   Carter, J F ^l   Gillman, J C ^l   Mack, D ^l   Benson Cooper, D ^l   Marini, G ^m   Simoncini, E ^m   Marpicati, P ^m   Sartori, U ^m   Barni, A ^m   Morassi, L ^m   Grigolato, P ^m   DiLorenzo, D ^m   Albertini, A ^m   Marinone, G ^m   Zorzi, M ^m   Hacking, A ⁿ   Dent, D M ⁿ   Terblanche, J ⁿ   Tiltmann, A ⁿ   Gudgeon, A ⁿ   Dowdle, E ⁿ   Palmer, P ⁿ   Schmidt, C G ^o   Hoffken K ^o   Schuning F ^o   Leder, L D ^o   Ludwig, H ^o   Callies, R ^o   Schindler, A E ^o,p   Faber, P ^p   Schnurch H G ^p   Bender, H ^p   Bojar, H ^p   Save Soderbergh J ^q   Cahlin, E ^q   Nilsson, S ^q   Fornander, J ^q   Salander, H ^q   Johnsen, Ch ^q   Ruusvik, O ^q   Ostberg, G ^q   Mattsson, L ^q   Backstrom, C G ^q   Bergegardh, S ^q   Ekelond, G ^q   Hessman, Y ^q   Nelzen, O ^q   Dahlin, S ^q   Wallin, G ^q   Ivarsson, L ^q   Thoren, O ^q   Lundell, L ^q   Ljungqvist, U ^q   Novak, J ^e   Erzen, D ^e   Naglas, M ^e   Sencar, M ^e   Cervek, J ^e   Cerar, O ^e   Stabuc, B ^e   Golouh, R ^e   Lamovec, J ^e   Jancar, J ^e   Sebek, S ^e   Parbhoo, S ^r   Boessen, E ^r   more..

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c IBCSG Coordinating Center   (Switzerland)

^d Ospedale Civico Lugano   (Switzerland)

^e INSTITUTE OF ONCOLOGY   (Slovenia)

^f CANCER EPIDEMIOLOGY CENTRE   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j International Breast Cancer Study Group   (Switzerland)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l Auckland Breast Cancer Study Group   (New Zealand)

^m SPEDALI CIVILI   (Italy)

ⁿ UNIVERSITY OF CAPE TOWN   (South Africa)

^o UNIVERSITY HOSPITAL ESSEN   (Germany)

^p HEINRICH HEINE UNIVERSITY   (Germany)

^q W Swedish Breast Cancer Study Group   (Sweden)

^r ROYAL FREE HOSPITAL   (United Kingdom)

more..

Author keywords

5 fluorouracil; Breast cancer; Chemotherapy; Cyclophosphamide; Dose; Methotrexate

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CYTOTOXICITY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RETROSPECTIVE STUDIES;

EID: 0032190483     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00209-3     Document Type: Article

References (37)

1. 1. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 1988, 6, 1501-1515.
2. 2. DeVita VT. Dose-response is alive and well. J Clin Oncol 1986, 4, 1157-1159.
3. 3. Von Hoff DD, Clark GM, Weiss GR, et al. Use of in vitro dose-response effects in select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 1986, 4, 1827-1834.
4. 4. Schabel FM, Griswold DP, Corbett TH, et al. Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer 1984, 54, 1160-1167.
5. 5. Hill RP, Stanley JA. Pulmonary metastases of the Lewis lung tumor-cell kinetics and response to cyclophosphamide at different sizes. Cancer Treat Rep 1977, 61, 29-36.
6. 6. Pinkel D, Hernandez D, Borella L, et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 1971, 27, 247-256.
7. 7. O'Brian RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977, 39, 1940-1948.
8. 8. Samson MK, Rivkin SE, Jones SE, et al. Dose-response and dose-survival advantage for high-versus-low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer 1984, 53, 1029-1035.
9. 9. Schnipper LE. Clinical implications of tumor-cell heterogeneity. N Engl J Med 1986, 314, 1423-1431.
10. 10. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981, 304, 10-15.
11. 11. Bonadonna G, Valagussa P, Rossi A, et al. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985, 5, 95-115.
12. 12. Ahmann D, O'Fallon J, Scanlon P, et al. A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol 1982, 5, 371-381.
13. 13. Hakes T, Geller N, Petroni G, et al. Confirmation of dose-survival relationship in breast adjuvant chemotherapy. Proc Am Soc Clin Oncol 1984, 3, 122.
14. 14. Howell A, Rubens RD, Bush H, et al. A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. In Senn HJ, ed. Recent Results in Cancer Research. Adjuvant Chemotherapy of Breast Cancer. Heidelberg, Springer, 1984.
15. 15. Wallgren A, Baral E, Beling U, et al. Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer. In Senn HJ, ed. Recent Results in Cancer Research. Adjuvant Chemotherapy of Breast Cancer. Heidelberg, Springer, 1984.
16. 16. Taylor IV SG, Tormey DC, Knuiman MJ, et al. Dose analysis for adjuvant trials in node positive breast cancer. The ECOG trials. Proc Am Soc Clin Oncol 1988, 7, 11.
17. 17. Senn HJ, Jungi WF, Amgwerd R, et al. Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer; 8-year results. In Senn HJ, ed. Recent Results in Cancer Research. Adjuvant Chemotherapy of Breast Cancer. Heidelberg, Springer, 1984.
18. 18. Mouridsen HT, Rose C, Brincker H, et al. Adjuvant systemic therapy in high-risk breast cancer. The Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. In Senn HJ, ed. Recent Results in Cancer Research. Adjuvant Chemotherapy of Breast Cancer. Heidelberg, Springer, 1984.
19. 19. Velez-Garcia E, Carpenter Jr JT, Moore M, et al. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: progress report of a Southeastern Cancer Study Group (SEG) trial. In Salmon SE, ed. Adjuvant Therapy of Cancer V. Philadelphia, Grune & Stratton, 1987.
20. 20. Korzun A, Norton L, Perloff M, et al. Clinical equivalence despite dosage differences of two schedules of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) for adjuvant therapy of node-positive stage II breast cancer. Proc Am Soc Clin Oncol 1988, 7, 12.
21. 21. Canellos GP. The dose dilemma. J Clin Oncol 1988, 6, 1363-1364.
22. 22. Redmond C, Fisher B, Wjeand HS. The methodologie dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 1983, 67, 519-526.
23. 23. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast cancer. N Engl J Med 1994, 330, 1253-1259.
24. 24. Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985, 45, 4454-4459.
25. 25. Ludwig Breast Cancer Study Group. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1985, 3, 1059-1067.
26. 26. Ludwig Breast Cancer Study Group. Randomized trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984, i, 1256-1260.
27. 27. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988, 319, 677-683.
28. 28. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response category. J Clin Oncol 1983, 1, 710-719.
29. 29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958, 53, 457-481.
30. 30. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B (Methodology) 1972, 34, 187-220.
31. 31. Hrynjuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986, 4, 1162-1170.
32. 32. Hrynjuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984, 2, 1281-1288.
33. 33. Gelman RS, Henderson IC. A reanalysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. SAKK Bull 1987, 1, 10-12.
34. 34. Muss HB, Thor AD, Berry DA. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 1994, 30, 1260-1266.
35. 35. Gusterson BA, Gelber RD, Goldhirsch A. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992, 10, 1049-1056.
36. 36. Levine M, Bramwell V, Pritchard K, et al. CEF versus CMF in premenopausal women - recent update. Eur J Cancer 1998, 34(Supp.), 15.
37. 37. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997, 89, 1673-1682.